Welcome to our dedicated page for Eupraxia Pharmac SEC filings (Ticker: EPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eupraxia Pharmaceuticals Inc. (EPRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market and Toronto Stock Exchange. Eupraxia files under the multijurisdictional disclosure system, using Form 40-F for annual reporting and Form 6-K for current reports under the Securities Exchange Act of 1934.
Recent Form 6-K submissions for Eupraxia include press releases, consolidated financial statements, and management’s discussion and analysis for specific periods. For example, filings incorporate interim financial statements and MD&A for quarters ended June 30 and September 30, as well as press releases summarizing clinical data from the RESOLVE trial, financial results, and details of public offerings of common shares. Some 6-Ks also attach material change reports, underwriting agreements, and certifications of interim filings by senior officers.
For investors analyzing EPRX, these filings are key sources of information on clinical development, financial position, and capital markets activity. They describe the status of EP-104GI and EP-104IAR, outline risk factors and forward-looking statements, and explain how proceeds from offerings are intended to support clinical trials, regulatory submissions, manufacturing scale-up, and pipeline expansion. They also discuss operational considerations such as reliance on third-party manufacturers and contract research organizations, and potential impacts of tariffs on clinical supplies.
On Stock Titan, Eupraxia’s filings are updated as new documents are posted to EDGAR, and AI-powered summaries help interpret lengthy exhibits. Users can quickly see which 6-Ks contain financial statements, which include clinical data press releases, and how each filing fits into the broader narrative of EPRX’s development programs and funding strategy.
Eupraxia Pharmaceuticals reported encouraging six-month symptom data from the highest dose cohort in the Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis. In the top dose group (n=3), patients showed a mean 4-point reduction in Straumann Dysphagia Index scores, where a 3-point drop is considered clinical remission.
Across dose cohorts 4-9, 59% of patients achieved clinical remission at 12 weeks, 76% of evaluable patients maintained remission at 24 weeks, and 67% at 52 weeks. A new 6 mg/site cohort using larger catheters (Cohort 8b) showed substantially better histologic, symptom, and eosinophil reductions than an earlier 6 mg/site cohort, supporting improved drug delivery.
EP-104GI has been well tolerated, with 31 patients and over 220 patient-months of follow-up, no serious adverse events, and no oropharyngeal candidiasis or adrenal or glucose issues reported. The randomized, placebo-controlled Phase 2b portion of RESOLVE, testing 120 mg and 160 mg doses, is ongoing, with top-line data expected in Q3 2026.
Joseph S. Freedman filed Amendment No. 2 to his Schedule 13D on Eupraxia Pharmaceuticals Inc., updating his ownership and recent share purchases. He is deemed to beneficially own 5,843,215 Eupraxia securities, representing 9.0% of the company’s common shares as calculated in the filing.
This total reflects common shares, Series 1 preferred shares, options for 155,000 common shares and 10,000 restricted stock units, as well as holdings by his spouse, a trust for which he is sole trustee, and his minor children, though he disclaims beneficial ownership of the children’s shares. On February 20, 2026, he bought 275,517 common shares and his spouse bought 4,483 shares in an underwritten public offering at $7.00 per share. On February 27, 2026, the trust exercised warrants for 150,000 shares at $2.20 per share, and his children exercised warrants for 20,000 shares at the same price.
Eupraxia Pharmaceuticals Inc. filed its Annual Report on Form 40-F for the fiscal year ended December 31, 2025, providing audited consolidated financial statements, management's discussion and analysis, and corporate governance disclosures.
Shares outstanding were 51,939,206 Common Shares and 8,355,638 Preferred Shares as of December 31, 2025. The filing incorporates the Annual Information Form, the 2025 audited financial statements, the MD&A, auditor consents, and officer certifications as exhibits.
Eupraxia Pharmaceuticals Inc. closed a public equity financing that raised gross proceeds of approximately US$63.2 million. The deal consisted of 7,607,145 common shares at US$7.00 per share and 1,428,571 pre-funded warrants priced at US$6.99999 each.
The company plans to use the funds mainly to advance its EP-104GI program for Eosinophilic Esophagitis, including preclinical work, a Phase 2 trial, preparations for a Phase 3 trial, and related manufacturing and regulatory activities. Additional proceeds will support broader gastrointestinal indications, pipeline research, business development, and general corporate purposes.
Eupraxia Pharmaceuticals closed a public offering raising approximately US$63.2 million in gross proceeds. The deal included 7,607,145 common shares at US$7.00 per share and pre-funded warrants to purchase up to 1,428,571 common shares at US$6.99999 each.
The company plans to use the funds mainly to advance its EP-104GI program for eosinophilic esophagitis through preclinical work, Phase 2 trials, Phase 3 preparations, and manufacturing, as well as expand EP-104GI into additional gastrointestinal indications and support broader pipeline, commercial, and corporate initiatives.
Eupraxia Pharmaceuticals Inc. has entered an underwriting agreement to sell 6,428,574 common shares and pre-funded warrants for up to 1,428,571 common shares, with an underwriters’ option to buy up to 1,178,571 additional shares. The firm shares are priced at $6.58 each and the pre-funded warrants at $6.57999 each, under a cross‑border offering led by Cantor Fitzgerald & Co. and conducted off an existing $200 million Form F‑10 shelf in Canada and the United States.
Eupraxia Pharmaceuticals Inc. is raising new capital through a public offering of common shares and pre-funded warrants for gross proceeds of approximately US$55 million. The company is selling 6,428,574 common shares at US$7.00 per share and pre-funded warrants to purchase up to 1,428,571 common shares at US$6.99999 each, with a nominal exercise price of C$0.00001 per warrant share.
The underwriters have a 30-day option to buy up to an additional 1,178,571 common shares on the same terms. Eupraxia plans to use the net proceeds mainly to advance its EP-104GI program for Eosinophilic Esophagitis through preclinical work, Phase 2 trials, Phase 3 preparations, and manufacturing, as well as to explore additional gastrointestinal indications, fund other pipeline candidates and business development, and support general corporate and growth-related needs.
Eupraxia Pharmaceuticals Inc. has filed a preliminary prospectus supplement for a proposed public offering of common shares, or pre-funded warrants, under its short form base shelf prospectus. The company also expects to grant underwriters a 30-day option to buy up to an additional 15% more securities.
The final size and pricing of the offering will be set based on market conditions and there is no assurance it will be completed. Eupraxia plans to use net proceeds mainly to advance its EP-104GI program for Eosinophilic Esophagitis through preclinical work, Phase 2 trials, Phase 3 preparation, and manufacturing.
Additional funds are expected to support new EP-104GI studies in other gastrointestinal indications, research on new pipeline candidates, business development, intellectual property expansion, and general corporate purposes, including salaries, working capital, facilities, and other administrative and capital needs.
Eupraxia Pharmaceuticals Inc. received an amended Schedule 13G showing that a group of related investment entities and individuals report beneficial ownership just under 10% of its common shares. Manchester Explorer, L.P. reports owning 4,597,217 shares, or 8.6% of the class, while Manchester Management entities each report 8.8%.
Individuals James E. Besser and Morgan C. Frank report beneficial ownership of 4,858,437 shares (9.1%) and 4,904,523 shares (9.2%), respectively, including both sole and shared voting and dispositive power. Most shares are held for advisory clients of Manchester Management PR, LLC, which generally do not exceed 5% ownership individually.
Eupraxia Pharmaceuticals reported encouraging new data from the Phase 1b/2a part of its RESOLVE trial testing EP-104GI in eosinophilic esophagitis.
At 12 weeks, patients on the highest dose (8mg/site, 20 sites, n=3) showed near-complete normalization of tissue health, with EoEHSS Grade improving 94% and Stage 97%. At 36 weeks, patients receiving 4mg/site (n=9) maintained the tissue gains first seen at week 12, and a clear dose-response was observed across dose levels.
Among patients with at least 60% of their esophagus treated, 58% achieved clinical remission at 12 weeks, 79% maintained remission at 24 weeks, and 67% maintained remission at 52 weeks. Across more than 200 patient-months of follow-up in 31 patients, EP-104GI was well tolerated, with no serious adverse events and no cases of oral candidiasis reported.